Bexarotene topical - Eisai Co Ltd
Alternative Names: Bexarotene gel; LGD 1069 topical; Targretin gel; Targretyn gel; Tarrexin gelLatest Information Update: 05 Nov 2021
At a glance
- Originator Ligand Pharmaceuticals
- Developer Eisai Co Ltd
- Class Antineoplastics; Antipsoriatics; Benzoic acids; Naphthalenes; Retinoids; Skin disorder therapies; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor agonists; Protein synthesis inhibitors; Retinoic acid receptor agonists; Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cutaneous T-cell lymphoma
- Discontinued Actinic keratosis; Alopecia areata; Atopic dermatitis; Basal cell cancer; Kaposi's sarcoma; Mycosis fungoides; Psoriasis